ERBB2 and neoplasm: Patients with an HR+/HER2−, PIK3CA wt tumor appeared to have shorter mOS, 18.9 months (CI 14.1–25.1), compared to patients with a tumor harboring any PIK3CA mutation (23.4 months; CI 17.0–27.6) (Table 4).